This is a working overview of peptide research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The two substrates of this enzyme are (S)-malic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are pyruvic acid, carbon dioxide, and reduced NADH. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-malate:NAD+ oxidoreductase (oxaloacetate-decarboxylating). Other names in common use include malic enzyme, pyruvic-malic carboxylase, NAD+-specific malic enzyme, NAD+-malic enzyme, and NAD+-linked malic enzyme. This enzyme participates in pyruvate metabolism.
Despite the bleak political situation (from the standpoint of Polish patriots), economic progress was made in the lands taken over by foreign powers because the period after the Congress of Vienna witnessed a significant development in the building of early industry. Economic historians have made new estimates on GDP per capita, 1790–1910. They confirm the hypothesis of semi-peripheral development of Polish territories in the 19th century and the slow process of catching-up with the core economies.
=== Propagation === While they can be successfully propagated in early spring, epimediums are best divided in late summer, with the aim of promoting rapid re-growth of roots and shoots before the onset of winter. Several breeders (in particular Darrell Diano Probst, Tim Branney & Robin White) have also undertaken their own hybridization programmes with the genus. Various new nursery selections are gradually appearing in the horticulture trade, the best of which extend the colour and shape range of the flowers available to the gardener.
== Tandem MS scan == This scan uses reverse-geometry (BE-type) instruments. These instruments use a front-end magnetic sector that allows for exclusive mass selection of the precursor ion. The fragmentation region is in-between the two analyzers. The electric sector scan gives the product-ion spectrum. MIKES can also be used for direct measurement of kinetic-energy release values.
The non-protein amino acid-accumulating clade, also known as the Canavanine-accumulating clade, is a clade of the flowering plant subfamily Faboideae (or Papilionoideae) that includes the majority of agriculturally-cultivated legumes. It is characterized by the accumulation of the non-proteinogenic amino acid canavanine in the seeds—a deterrent against herbivory. This phylogenetic trait was first recognized in the early 1980s. This clade is consistently resolved in molecular phylogenies. It contains many economically important genera, including Cicer, Glycine, Medicago, Phaseolus, Trifolium, Vicia, and Vigna.
Sources: en.wikipedia.org
The UK also condemned the execution of Farzad Bazoft, a journalist working for the British newspaper The Observer. Following Saddam's declaration that "binary chemical weapons" would be used on Israel if it used military force against Iraq, Washington halted part of its funding. A UN mission to the Israeli-occupied territories, where riots had resulted in Palestinian deaths, was vetoed by the US, making Iraq deeply skeptical of US foreign policy aims in the region, combined with the reliance of the US on Middle Eastern energy reserves.
These bound antibody/antigen complexes are then added to an antigen-coated well. The plate is washed, so unbound antibodies are removed. (The more antigen in the sample, the more Ag-Ab complexes are formed and so there are less unbound antibodies available to bind to the antigen in the well, hence "competition".) The secondary antibody, specific to the primary antibody, is added. This second antibody is coupled to the enzyme. A substrate is added, and remaining enzymes elicit a chromogenic or fluorescent signal. The reaction is stopped to prevent eventual saturation of the signal. Some competitive ELISA kits include enzyme-linked antigen rather than enzyme-linked antibody. The labeled antigen competes for primary antibody binding sites with the sample antigen (unlabeled). The less antigen in the sample, the more labeled antigen is retained in the well and the stronger the signal. Commonly, the antigen is not first positioned in the well. For the detection of HIV antibodies, the wells of microtiter plate are coated with the HIV antigen. Two specific antibodies are used, one conjugated with enzyme and the other present in serum (if serum is positive for the antibody). Cumulative competition occurs between the two antibodies for the same antigen, causing a stronger signal to be seen. Sera to be tested are added to these wells and incubated at 37 °C, and then washed. If antibodies are present, the antigen-antibody reaction occurs. No antigen is left for the enzyme-labelled specific HIV antibodies. These antibodies remain free upon addition and are washed off during washing.
== Applications == Because of their high mechanical, thermal and chemical stability, variable manufacturing of pore sizes with a small pore size distribution and variety of surface modifications, a wide array of applications are possible. The fact that porous glasses can be produced in many different shapes is another advantage for application in industry, medicine, pharmacy research, biotechnology and sensor technology. Porous glasses are ideal for material separation, because of the small pore size distribution. This is why they are used in gas chromatography, thin layer chromatography and affinity chromatography. An adaptation of stationary phase for a separation problem is possible by a specific modification of the surface of the porous glass. In biotechnology, porous glasses have benefits for the cleaning of DNA and the immobilization of enzymes or microorganisms. Controlled pore glass (CPG) with pore sizes between 50 and 300 nm is also excellently suited for the synthesis of oligonucleotides. In this application, a linker, a nucleoside or a non-nucleosidic compound, is first attached to the surface of CPG. The chain length of produced oligonucleotides is dependent on the pore size of CPG. In addition, porous glasses are used for manufacturing implants, especially dental implants, for which porous glass powder is processed with plastics to form a composite. The particle size and the pore size influence the elasticity of the composite so as to fit the optical and mechanical properties to surrounding tissue, for example, the appearance and hardness of dental enamel.
===== PurT GAR transformylase ===== PurT GAR transformylase requires formate as the formyl donor and ATP for catalysis. It has been estimated that PurT GAR transformylase carries out 14-50% of GAR formylations in E. coli. The enzyme is a member of the ATP-grasp superfamily of proteins.
==== 2005 Tbilisi grenade attack ==== On May 10, 2005, while President Bush was giving a speech in Freedom Square, Vladimir Arutyunian, a native Georgian who was born to a family of ethnic Armenians, threw a live Soviet-made RGD-5 hand grenade toward the podium. It landed in the crowd about 61 feet (19 m) from the podium after hitting a girl, but it did not detonate because a red tartan handkerchief was wrapped tightly around it, preventing the safety lever from detaching. Georgian president Mikheil Saakashvili was seated nearby. After escaping that day, Arutyunian was arrested in July 2005. During his arrest, he killed an Interior Ministry agent. He was convicted in January 2006 and given a life sentence.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.